Voyager Therapeutics, Inc.

As of September 12, 2025, Voyager Therapeutics shows a neutral technical trend with mixed signals, underperforming the S&P 500 significantly, with year-to-date and one-year returns of -20.90% and -28.01%, respectively.

As of March 11, 2025, Voyager Therapeutics, Inc. is considered risky and overvalued due to negative financial metrics and significant underperformance compared to the S&P 500, with a 1-year return of -28.01% and a negative return on equity of -31.06%.

As of March 11, 2025, Voyager Therapeutics, Inc. is considered overvalued and risky due to negative financial metrics, including a Price to Book Value of 0.72 and a year-to-date stock decline of 48.15%, significantly underperforming the S&P 500.

As of June 2, 2025, Voyager Therapeutics, Inc. shows a mildly bearish trend overall, with mixed signals from various indicators, including a bearish stance from Bollinger Bands and daily moving averages, while the weekly MACD is mildly bullish.

As of March 2022, the management team of Voyager Therapeutics, Inc. includes G. Andre Turenne as President and CEO, Nancy Vitale as a Director, and James Geraghty and Dr. Steven Hyman as Independent Directors.

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company focused on treating severe central nervous system diseases. As of March 2025, it reported net sales of $6 million and a net loss of $31 million, with a market cap of $172.65 million.

As of Jun 18, Voyager Therapeutics, Inc. has a market capitalization of 172.65 million, with net sales of 66.96 million and a net loss of 84.69 million over the latest four quarters. Shareholder's funds were 299.76 million, and total assets amounted to 393.05 million as of Dec 24.